Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (B...

• Author(s): Alves, Gilberto ; Figueiredo, Isabel ; Castel-Branco, Margarida ; Loureiro, Ana ; Fortuna, Ana ; Falcão, Amílcar ; Caramona, Margarida
• Date: 2007
• Persistent ID: http://hdl.handle.net/10316/2805
• Origin: Estudo Geral - Universidade de Coimbra
• Subject(s): eslicarbazepine acetate; BIA 2-093; oxcarbazepine; human plasma; bioanalytical method validation; enantioselective HPLC-UV method
• Document Type: Article
• Language: English

Description

Eslicarbazepine acetate (BIA 2-093) is a novel central nervous system drug undergoing clinical phase III trials for epilepsy and phase II trials for bipolar disorder. A simple and reliable chiral reversed-phase HPLC-UV method was developed and validated for the simultaneous determination of eslicarbazepine acetate, oxcarbazepine, S-licarbazepine and R-licarbazepine in human plasma. The analytes and internal standard were extracted from plasma by a solid-phase extraction using Waters Oasis® HLB cartridges. Chromatographic separation was achieved by isocratic elution with water–methanol (88:12, v/v), at a flow rate of 0.7 mL/min, on a LichroCART 250-4 ChiraDex (β-cyclodextrin, 5 μm) column at 30°C. All compounds were detected at 225 nm. Calibration curves were linear over the range 0.4–8 μg/mL for eslicarbazepine acetate and oxcarbazepine, and 0.4 – 80 μg/ mL for each licarbazepine enantiomer. The overall intra- and interday precision and accuracy did not exceed 15%. Mean relative recoveries varied from 94.00 to 102.23% and the limit of quantification of the assay was 0.4 μg/mL for all compounds. This method seems to be a useful tool for clinical research and therapeutic drug monitoring of eslicarbazepine acetate and its metabolites S-licarbazepine, R-licarbazepine and oxcarbazepine.